NanoViricides, Inc. (NYSE American: NNVC) announced it has entered into a securities purchase agreement with a single fundamental institutional investor for a registered direct offering expected to generate approximately $3.8 million in gross proceeds. The offering involves the sale of 2,516,339 common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase an equal number of common shares. Each full warrant has an exercise price of $1.75 per share and expires five and a half years after issuance. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions, with D. Boral Capital LLC serving as exclusive placement agent.
This capital infusion comes at a critical time for NanoViricides as the company advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company also has NV-HHV-1 in development for shingles. The funds will support the progression of NV-387 into Phase II human clinical trials, a milestone that could significantly impact the antiviral treatment landscape.
The importance of this funding extends beyond the company's pipeline. NanoViricides' nanoviricide technology platform, based on proprietary nanomaterials, offers a novel approach to antiviral therapy by targeting viruses directly. The company's broad-spectrum potential positions it as a key player in addressing unmet medical needs, particularly as respiratory viruses continue to pose global health threats. The registered direct offering structure, involving a single institutional investor, signals confidence in NanoViricides' technology and development strategy.
NanoViricides noted that its drug candidate NV-CoV-2 (API NV-387) does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, the encapsulated version could follow a more streamlined regulatory path if safety is comparable. However, the company also acknowledged the inherent risks of drug development, including the lengthy timeline and substantial capital required, as well as the uncertainty of clinical trial outcomes.
The offering details and company updates are available in the full press release at https://nnw.fm/2qH5W. For more information about NanoViricides and its technology, visit the company's website at https://www.nanoviricides.com. The latest news and updates relating to NNVC can be found in the company's newsroom at https://nnw.fm/NNVC.
